Genetically predicted telomere length and its relationship with neurodegenerative diseases and life expectancy

Blanca Rodríguez-Fernández a, Juan Domingo Gispert a,b,c,d, Roderic Guigo e,f, Arcadi Navarro a,e,f,g,h, Natalia Vilor-Tejedor a,e,f,i,1,2, Marta Crous-Bou b,j,k,⇑1,2

a BarcelonaBeta Brain Research Center – Pasqual Maragall Foundation, Barcelona, Spain
b IMIM – Hospital del Mar Medical Research Institute, Barcelona, Spain
c Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain
d Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
e Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Barcelona, Spain
f Universitat Pompeu Fabra (UPF), Barcelona, Spain
g Institut Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain
h Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
i Erasmus University Medical Center, Department of Clinical Genetics, Rotterdam, the Netherlands
j Institute of Evolutionary Biology (CSIC-UPF), Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Spain
k Universitas University Medical Center, Department of Clinical Genetics, Rotterdam, the Netherlands
l Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-Bellvitge Biomedical Research Center (IDIBELL), Hospitalet del Llobregat, Spain

ARTICLE INFO

Article history:
Received 8 March 2022
Received in revised form 3 August 2022
Accepted 3 August 2022
Available online 06 August 2022

Keywords:
Alzheimer’s disease
Life expectancy
Mendelian randomization
Neurodegenerative diseases
Telomere length

ABSTRACT

Telomere length (TL) is a biomarker of biological aging. Shorter telomeres have been associated with mortality and increased rates of age-related diseases. However, observational studies are unable to conclude whether TL is causally associated with those outcomes. Mendelian randomization (MR) was developed for assessing causality using genetic variants in epidemiological research. The objective of this study was to test the potential causal role of TL in neurodegenerative disorders and life expectancy through MR analysis. Summary level data were extracted from the most recent genome-wide association studies for TL, Alzheimer’s disease (AD), Parkinson’s disease, Frontotemporal dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy and life expectancy. MR estimates revealed that longer telomeres inferred a protective effect on risk of AD (OR = 0.964; adjusted p-value = 0.039). Moreover, longer telomeres were significantly associated with increased life expectancy (0.011; adjusted p-value = 0.039). Sensitivity analyses suggested evidence for directional pleiotropy in AD analyses. Our results showed that genetically predicted longer TL may increase life expectancy and play a protective causal effect on AD. We did not observe significant causal relationships between longer TL and other neurodegenerative diseases. This suggests that the involvement of TL on specific biological mechanisms might differ between AD and life expectancy, with respect to that in other neurodegenerative diseases. Moreover, the presence of pleiotropy may reflect the complex interplay between TL homeostasis and AD pathophysiology. Further observational studies are needed to confirm these results.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations: AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; CI, Confidence Interval; FTD, Frontotemporal dementia; GWAS, Genome-wide association study; IV, Instrumental Variable; IVW, Inverse-Variance Weighted; LRRC34, Leucine Rich Repeat Containing 34; MR, Mendelian Randomization; MR-PRESSO, MR-Pleiotropy Residual Sum and Outlier; OR, Odds ratio; PD, Parkinson’s disease; PSP, Progressive Supranuclear Palsy; SE, Standard Error; SNP, Single Nucleotide Polymorphism; TL, Telomere length.

⇑ Corresponding authors at: Catalan Institute of Oncology, Avda. Gran Via de l’Hospitalet 199-203, 08908 l’Hospitalet de Llobregat, Barcelona, Spain (Marta Crous-Bou), BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation, C. Wellington 30, 08005 Barcelona, Spain (Natalia Vilor-Tejedor), nvlilor@barcelonabeta.org (N. Vilor-Tejedor), marta.crous@iconcologia.net (M. Crous-Bou).

1 These authors contributed equally to this work.
2 ORCID: 0000-0003-4935-6721.
3 ORCID: 0000-0003-1493-4288.
1. Introduction

Aging is a major risk factor for most neurodegenerative diseases [1]. As life expectancy rises worldwide [2], the prevalence of neurodegenerative diseases also increases [3,4]. Numerous studies have speculated that neurodegenerative diseases are expressions of accelerated biological aging [1]. Traditionally, chronological age has been used as a proxy to estimate the gradual physiological deterioration that all living beings experience with time [5,6]. However, chronological age is an imperfect measure of biological aging, which is the true cause of morbidity and disability [7].

Telomere length (TL) is a well-known hallmark of biological aging [8], being telomere shortening associated with age-related diseases [9,10]. For instance, shorter telomeres have been found in Alzheimer’s disease (AD) patients [11,12], and it has been proposed as a valuable predictor of the AD incidence [13]. Nevertheless, its association with other neurodegenerative diseases and age-related processes remains unclear. At these crossroads, observational studies fail to discern whether aging-related changes in the brain are harbingers or mere consequences of neurodegeneration [14]. Mendelian Randomization (MR) approaches were developed to assess causality in observational studies. MR approaches use genetic instrumental variables (IVs) (i.e., Single Nucleotide Polymorphisms, SNPs) whose estimation of the exposure of interest (i.e., TL) is not influenced by confounding or reverse causation [15,16]. Previous MR studies have described potential causal effects of genetically predicted TL on the risk of AD [17–20]. How-ever, other MR studies failed to provide evidence of causal association [14]. Mendelian Randomization (MR) approaches were developed to assess causality in observational studies. MR approaches use genetic instrumental variables (IVs) (i.e., Single Nucleotide Polymorphisms, SNPs) whose estimation of the exposure of interest (i.e., TL) is not influenced by confounding or reverse causation [15,16]. Previous MR studies have described potential causal effects of genetically predicted TL on the risk of AD [17–20]. However, other MR studies failed to provide evidence of causal associations between TL and the risk of Parkinson’s disease (PD) [21] or Amyotrophic lateral sclerosis (ALS) [22].

The aim of this study was to assess the existence of common biological aging mechanisms (through telomere biology) to several neurodegenerative diseases and life expectancy. We perform multiple independent two-sample MR analyses to evaluate whether TL may play a causal role in the risk of neurodegenerative diseases and life expectancy by using instrumental variables from recent genome-wide association studies (GWAS).

2. Methods

2.1. Genetic instrumental variables of telomere length

Summary statistics from a genome-wide meta-analysis of leukocyte TL across large-scale European-descent studies including up to 78,592 individuals were obtained from [23]. We selected summary data (i.e., allele frequency, beta value, standard error, and p-values) for 21 SNPs genome-wide associated with leukocyte TL (p-value < 5 × 10^{-8}) (Supplementary Table S1). Further details of the GWAS can be found in Supplementary Table S2.

2.2. Genome-wide association study data for neurodegenerative conditions

We used summary-level data from the most recent large-scale GWAS on five neurodegenerative diseases: AD (N = 455,258) [24], Parkinson’s disease (PD) (N = 1,437,688) [25], Frontotemporal dementia (FTD) (N = 6,462) [26], Amyotrophic lateral sclerosis (ALS) (N = 36,052) [27] and Progressive Supranuclear Palsy (PSP) (N = 12,308) [28]. Further details of the GWASs can be found in Supplementary Table S2. To reduce potential bias from population stratification, we only drew on summary-level data from European-descent individuals. Proxies for the genetic instrumental missing variables were included when possible through LDLink [29] (Supplementary Table S3).

2.3. Genome-wide association study data for life expectancy

For life expectancy, we used summary-level data from a GWAS using age at death of parents of middle-aged UK Biobank participants of European descent (N = 45,627 with age at death data for both parents, excluding early deaths) [30]. Further details can be found in Supplementary Table S2.

2.4. Statistical analysis

Alleles were harmonized to take as reference the effect allele associated with longer TL. In this study, we used Inverse Variance Weighted (IVW) [31], MR-Egger regression [32], weighted median [33] and maximum likelihood [34] methods with summarized data to estimate the causal effect of genetically predicted longer TL on the outcomes of the study. MR-Egger regression intercept-test [32], leave-one-SNP-out and Cochran Q statistic [35] were used as ad hoc sensitivity analysis for evaluating the robustness of significant results. MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) was also used to identify horizontal pleiotropic outliers [36]. Effect sizes were reported in Odds Ratio (OR) for all the pathologies and the SD change in life expectancy (Δlifexp) per copy of the allele associated with longer telomere length. False Discovery Rate corrections for multiple comparisons were performed at significance level 0.05. MR-Egger regression intercept-test was used as ad hoc sensitivity analysis for evaluating directional pleiotropy [37]. P-values for intercept terms below 0.05 were indicators of pleiotropy. All analyses were conducted under R software, version 4.1.0 [38]. MR analyses were performed using the MendelianRandomization package in R [39]. Further details about the statistical procedure can be found in Supplementary Methods.

3. Results

IVW estimates revealed that longer TL inferred a protective effect on risk of AD (OR_{IVW} = 0.964; q-value = 0.039) (Table 1; Fig. 1). Maximum likelihood, MR-Egger regression, weighted median and weighted mode methods suggested similar protective effects. MR-Egger intercept test provided evidence for directional pleiotropy in AD analyses (p-value = 0.021). Nevertheless, there was no sign of increased heterogeneity according to both Cochran Q and MR-PRESSO (Table 1). IVW leave-one-out analysis showed MR estimates did not fluctuate after sequentially removing each of the 21 SNPs used as IVs (Supplementary Figure S1). No statistically significant associations were identified between genetically predicted longer TL and other neurodegenerative diseases (Supplementary Table S4; Supplementary Figures S2-S5). Leave-one-out analysis showed similar null effects when sequentially leaving out genetic variants from the analyses (Supplementary Figures S6-S9).

Moreover, longer TL was significantly associated with increased life expectancy (Δlifexp = 0.011; q-value = 0.039) (Fig. 2). Maximum likelihood, MR-Egger regression weighted median and weighted mode methods suggested analogous patterns of effect on life expectancy. In this case, MR-Egger intercept test did not suggest the presence of unbalanced directional pleiotropy (p-value = 0.462). Cochran Q and MR-PRESSO further supported the absence of heterogeneity in MR estimates (Table 1). Leave-one-out analysis showed IVW estimates lost significance when excluding rs10936600 from life expectancy analysis (Fig. 3).

4. Discussion

In this study, we explored the potential causal role of genetically predicted longer TL on the risk of neurodegenerative diseases.
and life expectancy through a multiple independent two-sample MR approach. We observed that genetically predicted longer TL was associated with increased life expectancy and lower risk of developing AD. No associations were observed in relation to other neurodegenerative diseases.

Our study confirms and extends previous MR studies regarding TL association with AD risk [17–20]. Nevertheless, we observed evidence of directional pleiotropy and AD estimates were relatively inconsistent when using several MR methods. Interestingly, [40] reported a similar pattern of MR estimates when using summary-level data from [24], where AD cases were both clinically diagnosed or AD-by-proxy (i.e., based on parental diagnoses). Despite the heritability of sporadic AD (~80%) [41], and the proven value of proxy case-control association studies [42], this could partially explain the decreased statistical power to detect consistent causal associations through robust MR methods.

We did not find further significant associations between genetically predicted TL and other neurodegenerative disease, which also confirms results from previous studies. For instance, two previous MR studies did not find significant causal associations between TL and the risk of PD [21], ALS and FTD [22]. Additionally, most observational studies showed contradictory results [43–45]. On the other hand, as far as we know, no previous MR studies have evaluated the causal role of TL on PSP. Although neurodegenerative diseases share common pathological pathways [46], our results might suggest that different hallmarks of aging could distinctly

Table 1

Mendelian randomization results for the relationship between genetically predicted longer telomere length, life expectancy and Alzheimer’s disease.

| Causal inference methods       | Life expectancy | Alzheimer’s disease |
|-------------------------------|-----------------|---------------------|
|                               | b  | SE  | p-value | q-value | OR   | 95 % CI | p-value | q-value |
| Inverse-variance weighted     | 0.011 | 0.004 | 0.010   | 0.039   | 0.964 | (0.936, 0.992) | 0.013   | 0.039   |
| Maximum likelihood            | 0.011 | 0.004 | 0.010   | 0.043   | 0.964 | (0.936, 0.993) | 0.014   | 0.043   |
| MR-Egger regression           | 0.020 | 0.013 | 0.113   | 0.339   | 0.884 | (0.818, 0.956) | 0.002   | 0.012   |
| Weighted median               | 0.013 | 0.006 | 0.038   | 0.165   | 0.966 | (0.932, 1.001) | 0.055   | 0.165   |
| Weighted mode                 | 0.021 | 0.009 | 0.021   | 0.126   | 0.976 | (0.934, 1.020) | 0.282   | 0.432   |

Sensitivity methods

| p-value | p-value |
|---------|---------|
| Cochran Q heterogeneity test | 0.978 | 0.101 |
| MR-PRESSO, global test | 0.982 | 0.106 |
| MR-Egger, intercept test | 0.462 | 0.021 |

Legend: CI, Confidence Intervals; MR, Mendelian Randomization; OR, Odds Ratio; SE, Standard Error; PRESSO, Pleiotropy RESidual Sum and Outlier.

Fig. 1. Scatter plot representing the significant causal effects of genetically predicted longer telomere length on Alzheimer’s disease risk. The slope of the line represents the Inverse-Variance Weighted causal estimate.
Fig. 2. Scatter plot representing the significant causal effects of genetically predicted longer telomere length on life expectancy. The slope of the line represents the Inverse-Variance Weighted causal estimate.

Fig. 3. Leave-one-out permutation analysis plot for life expectancy obtained by leaving out the SNP indicated and repeating the Inverse-Variance Weighted method with the rest of the instrumental variables.
interact with the complex etiology of these diseases [3,47]. Indeed, a composite biomarker panel of aging could increase the predictive power of these studies by pointing to different aspects of the aging process [48].

Additionally, we observed a statistically significant association between genetically predicted longer TL and increased life expectancy. Telomere shortening rate is known to predict species lifespan [49]. Nonetheless, little evidence of association between genetically predicted TL and parental lifespan has been previously described [50]. Importantly, we found that rs10936600, located at the leucine rich repeat (LRRC34) gene, was primarily driving the results of the MR analysis. Although the role of LRRC34 in telomere biology is not fully understood yet, gene-enrichment analysis has identified LRRC34 as the most significant gene associated with telomere length [51].

Therefore, our results support a potential causal relationship between shorter telomeres, AD risk, and increased life expectancy. Indeed, [30] described that offspring of longer-lived parents had more protective alleles for AD. Interestingly, AD contributes to a shortened life expectancy, although non-Alzheimer’s dementia usually show shorter life expectancy than AD [52]. Together with our results, this suggests that telomere biology might play a shared role in life expectancy and the pathophysiology of AD but no other neurodegenerative processes. Nonetheless, the higher prevalence of AD compared to other neurodegenerative diseases could also explain our results [4].

The causal effect of TL cannot be empirically tested in humans; therefore, MR approach provides a unique opportunity to disentangle the effect of TL in human health. Nevertheless, our study is not free of limitations. On the one hand, we found evidence of directional pleiotropy on AD analysis. Although supplementary sensitivity analyses did not support the presence of increased heterogeneity, IVW estimates could be biased in the presence of pleiotropy [33]. In this sense, although robust MR methods produced similar patterns of effects, the lack of significant associations encountered by applying the generally conservative MR methods (i.e., weighted median and weighted mode) could indicate a lack of statistical power or the presence of non-valid instrumental variants in AD analyses [37]. Indeed, we cannot fully ensure other MR assumptions have not been violated. In addition, proxies for some SNPs were used as IVs in MR analyses on PD, FTD and PSP. On the other hand, MR statistical power is dependent on the sample size of each GWAS. In this sense, the GWAS of FTD included a relatively small sample size (N cases = 2,154) and different FTD subtypes [25], which could explain the wide confidence intervals obtained in MR analyses (Supplementary Table S4). Moreover, the GWAS included in the MR analyses were exclusively performed in individuals of European ancestry, thus these results should not be extrapolated to other populations. Finally, telomere length in the GWAS [23] was measured in leukocytes. Although leukocyte TL is a valid proxy of TL in other tissue types including the brain [53], measuring TL among distinct brain cell types could help addressing the molecular mechanisms that connect telomere biology to AD risk.

As future research, MR analysis focused on addressing the role of TL on the pathological mechanisms of neurodegeneration could further help to identify which molecular pathways are involved in this potential causal association. Furthermore, the use of meta-GWAS including both larger samples and higher number of cases will increase the statistical power of future MR analysis. Finally, further observational studies could help to elucidate such associations.

Funding

This project has received funding from the Alzheimer’s Association (Grant AARG-19-618265). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) Ministry of Science and Innovation– Spanish State Research Agency. NV-T is funded by a postdoctoral grant, Juan de la Cierva Programme (IJC2020-043216-I). All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme / Generalitat de Catalunya.

CRediT authorship contribution statement

Blanca Rodríguez-Fernández: Conceptualization, Data curation, Methodology, Formal analysis, Visualization, Writing – original draft. Juan Domingo Gispert: Writing – review & editing. Roderic Guigo: Writing – review & editing. Arcadi Navarro: Writing – review & editing. Natalia Vilor-Tejedor: Conceptualization, Methodology, Supervision, Writing – review & editing. Marta Crous-Bou: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank the International FTD-Genetics Consortium (IFGC) for the summary data. We additionally thank all the Consortium members involved in the analysis and generation of summary statistics used in this project: Leukocyte Telomere Length (https://doi.org/10.1016/j.ajhg.2020.02.006); Alzheimer’s Disease (https://ctg.cncr.nl/software/summary_statistics); Frontotemporal Dementia (https://ifgsite.wordpress.com/data-access/); Parkinson’s Disease (https://drive.google.com/file/d/1FZ9UI9LAqyWnyNBxbx6gOIUAnubN/view?usp=sharing); Semantic Dementia (https://ifgsite.wordpress.com/data-access/); Life Expectancy (http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001- GCST004000/GCST003395/results.UKBiobank_9millionSNPs.parents_lifespan.Pilling_et_al_2016_top_1_percent.txt). Schematic representations were created with Biorender.com.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2022.08.006.

References

[1] Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation. Nature 2016;539:180–6. https://doi.org/10.1038/nature20411.
[2] United Nations Department of Economic and Social Affairs, Population Division (2020). World Population Ageing 2020 Highlights: Living arrangements of older persons (ST/ESA/SER.A/451).
[3] Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 2019;15:565–81.
[4] Feigin VL, Nichols E, Alam T, Banack MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:459–80. https://doi.org/10.1016/S1474-4422(18)30499-X.
[5] Carmona B, Michan S. Biology of Healthy Aging and Longevity. Rev Investig Clin n.d.;68:7–16.
[6] Fuellen G, Jansen L, Cohen AA, Luynen W, Gogol M, Simmel A, et al. Health and aging: unifying concepts, scores biomarkers and pathways. Aging Dis 2019;10:483. https://doi.org/10.14336/AD.2019.1030.
[7] Higgins-Chen AT, Thrush KL, Levine ME. Aging biomarkers and the brain. Semin Cell Dev Biol 2021;116:180–93. https://doi.org/10.1016/J.SEMCDB.2021.01.003.
B. Rodríguez-Fernández, J.D. Gispert, R. Guigo et al.

R Core Team. R: A Language and Environment for Statistical Computing. R Project Foundation for Statistical Computing; 2022

B. Rodríguez-Fernández, J.D. Gispert, R. Guigo et al. Computational and Structural Biotechnology Journal 20 (2022) 4251–4256

[19] Scheller Madrid A, Rasmussen KL, Rode L, Frikke-Schmidt R, Nordestgaard BG, Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Fu J, Ji X, Liu J, Chen X, Shang H. Meta-analysis of the connection between Alzheimer disease and telomere length in Alzheimer’s disease. J Gerontol Ser B: BioSci Med Sci 2016;71:1089–73. https://doi.org/10.1093/geronb/gow053.

[25] Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Fu J, Ji X, Liu J, Chen X, Shang H. Meta-analysis of the connection between Alzheimer disease and telomere length in Alzheimer’s disease. J Gerontol Ser B: BioSci Med Sci 2016;71:1089–73. https://doi.org/10.1093/geronb/gow053.

[124] Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1134–217. https://doi.org/10.1016/j.cell.2013.05.035.

[42] Vaiserman A, Krasnienkov D. Telomere length as a marker of biological age: a review and meta-analysis. BMJ 2014;349. https://doi.org/10.1136/BMJ.G4227.

[22] Gao Y, Wang T, Yu X, Ferrari R, Hernandez DG, Nalls MA, et al. Mendelian randomization: Moving beyond the NOME assumption. Int J Epidemiol 2019;48:728–42. https://doi.org/10.1093/ije/dyyz258.

[10] Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science (80-) 2015;350:1191–8. https://doi.org/10.1126/SCIENCE.AAB3395.

[53] Liang CS, Li DJ, Yang FC, Tseng PT, Carvalho AF, Stubbs B, et al. Mortality rates in non-APOE epsilon4 carriers. Aging (Albany NY) 2016;8:547–60. https://doi.org/10.1080/21678421.2016.1200149.

[31] Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013;37:63–65. https://doi.org/10.1002/GBE.174.

[20] Bowden J, Smith GD, Burgess S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512–25. https://doi.org/10.1093/IJE/DYU080.

[21] Chen R, Zhan Y. Association between telomere length and Parkinson’s disease: a meta-analysis of genome-wide association studies. Front Psychiatry 2019;10. https://doi.org/10.3389/FPSYT.2019.00843.

[22] Gao Y, Wang T, Yu X, Ferrari R, Hernandez DG, Nalls MA, et al. Mendelian randomization: Moving beyond the NOME assumption. Int J Epidemiol 2019;48:728–42. https://doi.org/10.1093/ije/dyyz258.

[11] Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Fu J, Ji X, Liu J, Chen X, Shang H. Meta-analysis of the connection between Alzheimer disease and telomere length in Alzheimer’s disease. J Gerontol Ser B: BioSci Med Sci 2016;71:1089–73. https://doi.org/10.1093/geronb/gow053.

[11] Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Fu J, Ji X, Liu J, Chen X, Shang H. Meta-analysis of the connection between Alzheimer disease and telomere length in Alzheimer’s disease. J Gerontol Ser B: BioSci Med Sci 2016;71:1089–73. https://doi.org/10.1093/geronb/gow053.

[13] Hackenhaas FS, Josefsson M, Adolffson AN, Landfors M, Kuppi K, Hultdin M, et al. Short leukocyte telomeres predict 25-year Alzheimer’s disease incidence in non-APOE ε4-carriers. Alzheimer’s Res Ther 2021;13. https://doi.org/10.1186/S13195-021-00871-Y.

[48] Eitan E, Hutchison ER, Mattson MP. Telomere shortening in neurological disorders. Front Cell Neurosci 2020;14. https://doi.org/10.3389/FNEUR.2020.00157.

[49] Vaiserman A, Krasnienkov D. Telomere length as a marker of biological age: a review and meta-analysis. BMJ 2014;349. https://doi.org/10.1136/BMJ.G4227.

[50] Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2020;4. https://doi.org/10.12688/WellcomeOpenRes.15555.2.

[42] Vaiserman A, Krasnienkov D. Telomere length as a marker of biological age: a review and meta-analysis. BMJ 2014;349. https://doi.org/10.1136/BMJ.G4227.

[19] Scheller Madrid A, Rasmussen KL, Rode L, Frikke-Schmidt R, Nordestgaard BG, Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Fu J, Ji X, Liu J, Chen X, Shang H. Meta-analysis of the connection between Alzheimer disease and telomere length in Alzheimer’s disease. J Gerontol Ser B: BioSci Med Sci 2016;71:1089–73. https://doi.org/10.1093/geronb/gow053.

[11] Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Fu J, Ji X, Liu J, Chen X, Shang H. Meta-analysis of the connection between Alzheimer disease and telomere length in Alzheimer’s disease. J Gerontol Ser B: BioSci Med Sci 2016;71:1089–73. https://doi.org/10.1093/geronb/gow053.

[124] Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1134–217. https://doi.org/10.1016/j.cell.2013.05.035.

[42] Vaiserman A, Krasnienkov D. Telomere length as a marker of biological age: a review and meta-analysis. BMJ 2014;349. https://doi.org/10.1136/BMJ.G4227.

[50] Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2020;4. https://doi.org/10.12688/WellcomeOpenRes.15555.2.

[50] Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2020;4. https://doi.org/10.12688/WellcomeOpenRes.15555.2.

[50] Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2020;4. https://doi.org/10.12688/WellcomeOpenRes.15555.2.

[50] Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2020;4. https://doi.org/10.12688/WellcomeOpenRes.15555.2.

[50] Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2020;4. https://doi.org/10.12688/WellcomeOpenRes.15555.2.

[50] Pilling LC, Atkins JL, Bowman K, Jones SE, Tyrrell J, Beaumont RN, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res 2020;4. https://doi.org/10.12688/WellcomeOpenRes.15555.2.